Other Events ·
On August 5, 2026, AVITA Medical entered into a Global Amendment with Stedical Scientific to expand its exclusive…
RCELAVITA Medical, Inc.
On August 5, 2026, AVITA Medical entered into a Global Amendment with Stedical Scientific to expand its exclusive distribution rights and adjust revenue sharing terms. In exchange for a $500,000 fee, the Company secured rights of first offer and refusal to expand territory into the European Union, United Kingdom, and Australia. Revenue shares from PermeaDerm sales increased to 67% for sheet form products and 80% for glove form products, subject to margin-based adjustments. The amendment imposes a $1.0 million revenue sharing payment requirement for 2026 with 20% annual growth through 2030, while waiving previous minimums. Stedical may also commercialize PermeaDerm in certain U.S. markets and Asia under specific manufacturing cost-plus pricing structures. AVITA Medical operates in the medical device industry, specializing in regenerative medicine products for wound care.